Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 1, 2015, Pages 173-182

  Koo, Dong Hoe ^a,b   Ryu, Min Hee ^a   Ryoo, Baek Yeol ^a   Beck, Mo Youl ^a   Na, Young Soon ^c   Shin, Jae Gook ^d,e   Lee, Sang Seop ^d,e   Kim, Eun Young ^d,e   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Asan Medical Center   (South Korea)

^d Inje University   (South Korea)

^e Inje University College of Medicine   (South Korea)

Author keywords

ABCG2; Gastrointestinal stromal tumor; Imatinib; Prognosis; Single nucleotide polymorphism

Indexed keywords

ALBUMIN; BREAST CANCER RESISTANCE PROTEIN; CREATININE; CYTOCHROME P450 3A5; HEMOGLOBIN; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TUMOR PROTEIN;

ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; BODY SURFACE; BODY WEIGHT; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; EXON; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; AMINO ACID SUBSTITUTION; BLOOD; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; GENETICS; METABOLISM; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY; SOUTH KOREA; SURVIVAL; UNIVERSITY HOSPITAL; VERY ELDERLY;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BENZAMIDES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84925230883     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2630-6     Document Type: Article

References (38)

1. Fletcher CD, Berman JJ, Corless C, Gorstein F., Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stro-mal tumors: a consensus approach. Int J Surg Pathol 10:81-89
2. Reichardt P, Reichardt A, Pink D (2011) Molecular targeted therapy of gastrointestinal stromal tumors. Curr Cancer Drug Targets 11:688-697
3. Plaat BE, Hollema H, Molenaar W.M., Torn Broers GH, Pijpe J, Mastik MF, Hoekstra H.J., van den Berg E, Scheper RJ, van der Graaf WT (2000) Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 18:3211-3220
4. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480
5. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher J.A., Corless CL, Fletcher CDM, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H (2008) Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620-625
6. Ryu MH, Kang WK, Bang Y.J., Lee KH, Shin DB, Ryoo BY, Roh J.K., Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK (2009) A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor. Oncology 76:326-332
7. Wang WL, Conley A, Reynoso D., Nolden L, Lazar AJ, George S, Trent JC (2011) Mechanisms of resistance to imatinib and suni-tinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 67(SUPPL. 1):S15-S24
8. Eechoute K, Sparreboom A, Burger H., Franke RM, Schiavon G, Verweij J, Loos W.J., Wiemer EA, Mathijssen RH (2011) Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 17:406-415
9. Burger H, van Tol H, Boersma AW, Brok M, Wiemer E.A., Stoter G., Nooter K (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104:2940-2942
10. Gurney H, Wong M, Balleine R.L., Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke C.L., Mann GJ, Collins M, Delforce SE, Lynch K, Schran H (2007) Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 82:33-40
11. Takahashi N, Miura M, Scott S.A., Kagaya H., Kameoka Y, Tagawa H, Saitoh H., Fujishima N, Yoshioka T, Hirokawa M, Sawada K (2010) Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 55:731-737
12. Oostendorp RL, Buckle T, Beijnen J.H., van Tellingen O, Schellens JH (2009) The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 27:31-40
13. Ieiri I, Takane H, Hirota T., Otsubo K, Higuchi S (2006) Genetic polymorphisms of drug transporters: pharmacokinetic and phar-macodynamic consequences in pharmacotherapy. Expert Opin Drug Metab Toxicol 2:651-674
14. Kim DH, Sriharsha L, Xu W., Kamel-Reid S, Liu X, Siminovitch K., Messner HA, Lipton JH (2009) Clinical relevance of a phar-macogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 15:4750-4758
15. Seong SJ, Lim M, Sohn S.K., Moon JH, Oh SJ, Kim BS, Ryoo H.M., Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Park SY, Yoon SS, Kim I, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Lee HW, Yoon YR (2013) Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol 24:756-760
16. Ni L-N, Li J-Y, Miao K-R, Qiao C, Zhang S-J, Qiu H-R, Qian S-X (2011) Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 28:265-269
17. Shinohara Y, Takahashi N, Nishiwaki K., Hino M, Kashimura M, Wakita H., Hatano Y, Hirasawa A, Nakagawa Y, Itoh K, Masuoka H, Aotsuka N, Matsuura Y, Takahara S, Sano K, Kuroki J, Hata T, Nakamae H, Mugitani A, Nakane T, Miyazaki Y, Niioka T, Miura M, Sawada K (2013) A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction. Haematologica 98:1407-1413
18. Bakhtiar R, Lohne J, Ramos L., Khemani L, Hayes M, Tse F (2002) High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spec-trometry. J Chromatogr B Anal Technol Biomed Life Sci 768: 325-340
19. Barrett JC, Fry B, Maller J., Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
20. Kang HJ, Ryu MH, Kim K.M., Park YS, Choi J, Ryoo BY, Kim W.H., Im SA, Bang YJ, Park SH, Lee JH, Chung IJ, Bae HI, Kim JG, Lee KH, Song HS, Kwon HC, Baek JH, Shin DB, Lee KE, Kang YK (2012) Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): the Korean GIST Study Group (KGSG) study. Acta Oncol 51:528-536
21. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohen-berger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093-1103
22. Antonescu CR, Besmer P, Guo T., Arkun K, Hom G, Koryotowski B., Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11:4182-4190
23. Gronchi A, Blay JY, Trent JC (2010) The role of high-dose imatinib in the management of patients with gastrointestinal stro-mal tumor. Cancer 116:1847-1858
24. Ozvegy C, Litman T, Szakacs G., Nagy Z, Bates S, Varadi A., Sarkadi B (2001) Functional characterization of the human mul-tidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 285:111-117
25. Robey RW, Massey PR, Amiri-Kordestani L, Bates SE (2010) ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem 10:625-633
26. Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K (2006) Association of enzyme and transporter genotypes with the pharmacoki-netics of imatinib. Clin Pharmacol Ther 80:192-201
27. Imai Y, Nakane M, Kage K., Tsukahara S, Ishikawa E, Tsuruo T., Miki Y, Sugimoto Y (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1:611-616
28. Pollex EK, Anger G, Hutson J., Koren G, Piquette-Miller M (2010) Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism. Drug Metab Dispos 38:740-744
29. Demetri GD, Wang Y, Wehrle E., Racine A, Nikolova Z, Blanke C.D., Joensuu H., von Mehren M (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresect-able/metastatic gastrointestinal stromal tumors. J Clin Oncol 27:3141-3147
30. Widmer N, Decosterd LA, Leyvraz S, Duchosal M.A., Rosselet A., Debiec-Rychter M, Csajka C, Biollaz J., Buclin T (2008) Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 98:1633-1640
31. Eechoute K, Fransson MN, Reyners A.K., de Jong FA, Sparreboom A, van der Graaf WT, Friberg LE, Schiavon G, Wiemer EA, Verweij J, Loos WJ, Mathijssen RH, De Giorgi U (2012) A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 18:5780-5787
32. Yoo C, Ryu MH, Ryoo B.Y., Beck MY, Kang YK (2013) Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. Invest New Drugs 31:1367-1374
33. Haouala A, Widmer N, Guidi M., Montemurro M, Leyvraz S, Buclin T., Eap CB, Decosterd LA, Csajka C (2013) Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. Br J Clin Pharmacol 75:1007-1018
34. Bihorel S, Camenisch G, Lemaire M., Scherrmann JM (2007) Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J Neurochem 102:1749-1757
35. Mlejnek P, Dolezel P, Faber E., Kosztyu P (2011) Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with p-glycoprotein in human leukemia cells. Ann Hematol 90:837-842
36. Cohen MH, Williams G, Johnson J.R., Duan J., Gobburu J, Rahman A, Benson K., Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic mye-logenous leukemia. Clin Cancer Res 8:935-942
37. Lepper ER, Nooter K, Verweij J., Acharya MR, Figg WD, Sparreboom A (2005) Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6:115-138
38. Lee SS, Jeong HE, Yi J.M., Jung HJ, Jang JE, Kim EY, Lee S.J., Shin JG (2007) Identification and functional assessment of BCRP polymorphisms in a Korean population. Drug Metab Dispos 35:623-632